Ipilimumab (New Therapeutic Indication) -- Benefit Assessment According to §35a Social Code Book V [Internet].

The aim of this report was to assess the added benefit of ipilimumab compared with dacarbazine as appropriate comparator therapy (ACT) in adult patients with advanced (unresectable or metastatic) melanoma who have not received prior therapy to treat advanced melanoma.

http://ift.tt/2siOrba